| ||||||||||
Between 2011 and 2013, Bristol's blood thinner Plavix, bipolar disorder treatment Abilify and blood pressure drug Avapro are expected to face low-cost generic rivals. Abilify had $2.6 billion in sales in 2009, and Avapro had $1.3 billion in sales the same year. Bristol had a total of $18.8 billion in sales that year.
In recent rounds of layoffs, Bristol-Myers said in December 2008 that it would eliminate 800 positions by the end of that year, a move to save $1 billion by 2012.
That came on top of $1.5 billion in cost cuts announced in December 2007, including eliminating about 4,300 jobs through 2010.
[Associated 
			Press; 
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
                    
                    Community |
                    Perspectives 
                    |
                    Law & Courts |
                    Leisure Time 
                    |
                    Spiritual Life | 
                    Health & Fitness | 
                    
                    Teen Scene
                    Calendar 
                    |
                    Letters to the Editor